NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
523
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
stocks
Bapcor is paying for the sins of its past
stocks
Overvalued ASX share as market underestimates downside risks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,401.00 | 27.30 | 0.29% |
CAC 40 | 8,206.07 | 31.87 | 0.39% |
DAX 40 | 24,258.80 | 427.81 | 1.80% |
Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
FTSE 100 | 9,403.57 | 49.00 | 0.52% |
HKSE | 26,206.17 | 347.34 | 1.34% |
NASDAQ | 22,990.54 | 310.57 | 1.37% |
Nikkei 225 | 49,835.43 | 649.93 | 1.32% |
NZX 50 Index | 13,334.06 | 10.90 | -0.08% |
S&P 500 | 6,735.13 | 71.12 | 1.07% |
S&P/ASX 200 | 9,103.00 | 27.10 | 0.30% |
SSE Composite Index | 3,879.92 | 16.02 | 0.41% |